B-cell depletion and efficacy outcomes with ofatumumab: Subgroup analysis from the pooled phase 3 asclepios i and ii trials

This article has no abstract
Epistemonikos ID: ad75681c0230b32b2cd8cce74282050a98eb1e08
First added on: Feb 12, 2025